Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects

Despite its importance in the physiopathology of HSV-1 and -2 infections, the cell-to-cell spreading mechanism is still poorly understood. The data shown here suggest that infection-elicited neutralizing antibodies capable of inhibiting cell-to-cell virus spread can be underrepresented in most infected subjects. These observations can be of great help in better understanding the role of humoral immunity in controlling virus reactivation and in the perspective of developing novel therapeutic strategies, studying novel correlates of protection, and designing effective vaccines. ABSTRACT Herpes simplex virus 1 (HSV-1) and HSV-2 can evade serum antibody-mediated neutralization through cell-to-cell transmission mechanisms, which represent one of the central steps in disease reactivation. To address the role of humoral immunity in controlling HSV-1 and HSV-2 replication, we analyzed serum samples from 44 HSV-1 and HSV-2 seropositive subjects by evaluating (i) their efficiency in binding both the purified viral particles and recombinant gD and gB viral glycoproteins, (ii) their neutralizing activity, and (iii) their capacity to inhibit the cell-to-cell virus passage in vitro. All of the sera were capable of binding gD, gB, and whole virions, and all sera significantly neutralized cell-free virus. However, neither whole sera nor purified serum IgG fraction was able to inhibit significantly cell-to-cell virus spreading in in vitro post-virus-entry infectious assays. Conversely, when spiked with an already described anti-gD human monoclonal neutralizing antibody capable of inhibiting HSV-1 and -2 cell-to-cell transmission, each serum boosted both its neutralizing and post-virus-entry inhibitory activity, with no interference exerted by serum antibody subpopulations. IMPORTANCE Despite its importance in the physiopathology of HSV-1 and -2 infections, the cell-to-cell spreading mechanism is still poorly understood. The data shown here suggest that infection-elicited neutralizing antibodies capable of inhibiting cell-to-cell virus spread can be underrepresented in most infected subjects. These observations can be of great help in better understanding the role of humoral immunity in controlling virus reactivation and in the perspective of developing novel therapeutic strategies, studying novel correlates of protection, and designing effective vaccines.

[1]  D. Lilleri,et al.  Human cytomegalovirus (HCMV)‐specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid‐organ transplant recipients , 2018, Journal of medical virology.

[2]  D. Cook,et al.  Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011 , 2018, The Journal of infectious diseases.

[3]  Nicola Clementi,et al.  Synergy evaluation of anti‐Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle , 2018, Antiviral research.

[4]  C. S. Nelson,et al.  Maternal immune correlates of protection against placental transmission of cytomegalovirus. , 2017, Placenta.

[5]  A. Tarr,et al.  Entry inhibition of HSV‐1 and ‐2 protects mice from viral lethal challenge , 2017, Antiviral research.

[6]  Nicola Clementi,et al.  Role and potential therapeutic use of antibodies against herpetic infections. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  S. Bailly,et al.  Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  Nicola Clementi,et al.  Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes. , 2016, Drug discovery today.

[9]  Karen G. Dowell,et al.  Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control , 2016, PLoS pathogens.

[10]  R. Eisenberg,et al.  Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific , 2015, Journal of Virology.

[11]  W. Jacobs,et al.  Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease , 2015, eLife.

[12]  Nicola Clementi,et al.  Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein , 2015, Gut.

[13]  T. Mertens,et al.  Natural Killer Cells Can Inhibit the Transmission of Human Cytomegalovirus in Cell Culture by Using Mechanisms from Innate and Adaptive Immune Responses , 2014, Journal of Virology.

[14]  R. Eisenberg,et al.  Dissection of the Antibody Response against Herpes Simplex Virus Glycoproteins in Naturally Infected Humans , 2014, Journal of Virology.

[15]  H. Friedman,et al.  Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. , 2014, The Journal of infectious diseases.

[16]  R. Eisenberg,et al.  Repertoire of Epitopes Recognized by Serum IgG from Humans Vaccinated with Herpes Simplex Virus 2 Glycoprotein D , 2014, Journal of Virology.

[17]  A. Steven,et al.  Mechanism of Neutralization of Herpes Simplex Virus by Antibodies Directed at the Fusion Domain of Glycoprotein B , 2013, Journal of Virology.

[18]  Guixiu Shi,et al.  Systemic Autoimmune Diseases , 2013, Clinical and Developmental Immunology.

[19]  M. Franti,et al.  Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. , 2013, Virology.

[20]  J. Schiffer Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection , 2013, Front. Immunol..

[21]  M. dal Peraro,et al.  Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides , 2013, Clinical & developmental immunology.

[22]  D. Jäger,et al.  Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody , 2013, Proceedings of the National Academy of Sciences.

[23]  D. Shah,et al.  Antibody biodistribution coefficients , 2013, mAbs.

[24]  Nicola Clementi,et al.  Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape? , 2012, Viruses.

[25]  D. Bernstein,et al.  Efficacy results of a trial of a herpes simplex vaccine. , 2012, The New England journal of medicine.

[26]  R. Eisenberg,et al.  Antibody-Induced Conformational Changes in Herpes Simplex Virus Glycoprotein gD Reveal New Targets for Virus Neutralization , 2011, Journal of Virology.

[27]  R. Eisenberg,et al.  Capturing the Herpes Simplex Virus Core Fusion Complex (gB-gH/gL) in an Acidic Environment , 2011, Journal of Virology.

[28]  D. Jäger,et al.  Impact of Valency of a Glycoprotein B-Specific Monoclonal Antibody on Neutralization of Herpes Simplex Virus , 2010, Journal of Virology.

[29]  P. Kalinski,et al.  Reevaluating the CD8 T-Cell Response to Herpes Simplex Virus Type 1: Involvement of CD8 T Cells Reactive to Subdominant Epitopes , 2008, Journal of Virology.

[30]  F. Gudé,et al.  Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities , 2007, Clinical and experimental immunology.

[31]  A. Tarr,et al.  Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein , 2007, Journal of Virology.

[32]  R. Eisenberg,et al.  Antigenic and Mutational Analyses of Herpes Simplex Virus Glycoprotein B Reveal Four Functional Regions , 2007, Journal of Virology.

[33]  F. Aoki,et al.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes. , 2002, The New England journal of medicine.

[34]  M. Muggeridge Characterization of cell-cell fusion mediated by herpes simplex virus 2 glycoproteins gB, gD, gH and gL in transfected cells. , 2000, The Journal of general virology.

[35]  A. Adimora,et al.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. , 1999, JAMA.

[36]  R. Rozenshteyn,et al.  Characterization of a Type-Common Human Recombinant Monoclonal Antibody to Herpes Simplex Virus with High Therapeutic Potential , 1998, Journal of Clinical Microbiology.

[37]  R. Eisenberg,et al.  Monoclonal Antibodies to Distinct Sites on Herpes Simplex Virus (HSV) Glycoprotein D Block HSV Binding to HVEM , 1998, Journal of Virology.

[38]  J. Lubinski,et al.  The gH-gL Complex of Herpes Simplex Virus (HSV) Stimulates Neutralizing Antibody and Protects Mice against HSV Type 1 Challenge , 1998, Journal of Virology.

[39]  G. Mertz,et al.  Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies , 1996, Journal of virology.

[40]  P. Fine,et al.  Correlates of vaccine-induced protection: methods and implications , 2013 .